Jay I. Phillips

Jay I. Phillips

Auto-generated profile, based on publicly available information

Jay I. Phillips

Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
JSJulie A. Saugstad
Julie A. Saugstad
TLTheresa Lusardi
Theresa Lusardi
KKKendall R. Van Keuren‐Jensen
Kendall R. Van Keuren‐Jensen
JPJay I. Phillips
Jay I. Phillips
BLBabett Lind
Babett Lind
FHFred H. Hochberg
Fred H. Hochberg
We examined the extracellular vesicle (EV) and RNA composition of pooled normal cerebrospinal fluid (CSF) samples and CSF from five major neurological disorders: Alzheimer's disease (AD), Parkinson's disease (PD), low‐grade glioma (LGG), glioblastoma multiforme (GBM), and subarachnoid haemorrhage (SAH), representing neurodegenerative disease, cancer, and severe acute brain injury. We evaluated: (I) size and quantity of EVs by nanoparticle tracking analysis (NTA) and vesicle flow cytometry (VFC), (II) RNA yield and purity using four RNA isolation kits, (III) replication of RNA yields within and between laboratories, and (IV) composition of total and EV RNAs by reverse transcription–quantitative polymerase chain reaction (RT‐qPCR) and RNA sequencing (RNASeq). The CSF contained ~106 EVs/μL by NTA and VFC. Brain tumour and SAH CSF contained more EVs and RNA relative to normal, AD, and PD. RT‐qPCR and RNASeq identified disease‐related populations of microRNAs and messenger RNAs (mRNAs) relative to normal CSF, in both total and EV fractions. This work presents relevant measures selected to inform the design of subsequent replicative CSF studies. The range of neurological diseases highlights variations in total and EV RNA content due to disease or collection site, revealing critical considerations guiding the selection of appropriate approaches and controls for CSF studies.

1 May 2002 in Current Genetics
Verified
Journal Article
Closed access
PDF file
FGFrits Goedegebuur
Frits Goedegebuur
TFTimothy Fowler
Timothy Fowler
JPJay Phillips
Jay Phillips
PKPim van der Kley
Pim van der Kley
PSPiet van Solingen
Piet van Solingen
SPScott D. Power
Scott D. Power

1 January 2014 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
TLTheresa Lusardi
Theresa Lusardi
SMStephanie J. Murphy
Stephanie J. Murphy
JPJay I. Phillips
Jay I. Phillips
YCYingxin Chen
Yingxin Chen
Catherine DavisCatherine Davis
Catherine Davis
JSJulie A. Saugstad
Julie A. Saugstad
Stroke occurs with greater frequency in men than in women across diverse ethnic backgrounds and nationalities. Work from our lab and others have revealed a sex-specific sensitivity to cerebral ischemia whereby males exhibit a larger extent of brain damage resulting from an ischemic event compared to females. Previous studies revealed that microRNA (miRNA) expression is regulated by cerebral ischemia in males; however, no studies to date have examined the effect of ischemia on miRNA responses in females. Thus, we examined miRNA responses in male and female brain in response to cerebral ischemia using miRNA arrays. These studies revealed that in male and female brains, ischemia leads to both a universal miRNA response as well as a sexually distinct response to challenge. Target prediction analysis of the miRNAs increased in male or female ischemic brain reveal sex-specific differences in gene targets and protein pathways. These data support that the mechanisms underlying sexually dimorphic responses to cerebral ischemia includes distinct changes in miRNAs in male and female brain, in addition to a miRNA signature response to ischemia that is common to both.

3 November 2012 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
BBBenedetta Belloni
Benedetta Belloni
CLChiara Lambertini
Chiara Lambertini
Paolo NuciforoPaolo Nuciforo
Paolo Nuciforo
JPJay Phillips
Jay Phillips
EBEric Bruening
Eric Bruening
RDReinhard Dummer
Reinhard Dummer
Formalin fixation and paraffin embedding present the standard procedures for conserving clinical tissues for histological analysis. However, molecular analysis is impaired by the cross linking properties of formalin. The PAXgene tissue system (PreAnalytix, Switzerland) is a new formalin-free tissue collection device. Aims In this study we aimed to evaluate this new tissue preservation technique in comparison with formalin fixation and fresh frozen tissue samples. Methods 12 melanoma biopsy samples were divided and fixed simultaneously with formalin, PAXgene or fresh frozen in liquid nitrogen and analysed with regard to morphology, immunohistochemistry, DNA and RNA content and quality. Markers of melanocytic differentiation and tumour cell proliferation were used. Results Morphology was well preserved in PAXPE samples. However, 5 out of 11 immunohistochemical markers showed significantly lower overall staining and staining intensity with PAXPE tissues in comparison with formalin-fixed, paraffin-embedded (FFPE). Increasing membrane permeability through adding a detergent did proportionally increase staining intensity in PAXPE samples. Amplification of different mRNA amplicons showed a direct relationship with the size of the amplicon with greater template integrity observed in PAXPE samples. Sequencing and mutational analysis of DNA samples were comparable for all the different fixation methods, while the level of DNA fragmentation seemed to be lower in PAXPE compared with FFPE tissues. Conclusions The switch from formalin to PAXgene fixation would require a re-evaluation of immunohistochemical markers and staining procedures originally developed for FFPE tissues. Our data demonstrate that PAXPE fixation offers some advantages concerning molecular analysis. However, these advantages would not justify substituting formalin fixation in any routine pathology laboratory.

23 June 2014 in Neurochemistry International
Verified
Journal Article
Closed access
SMStephanie J. Murphy
Stephanie J. Murphy
TLTheresa Lusardi
Theresa Lusardi
JPJay I. Phillips
Jay I. Phillips
JSJulie A. Saugstad
Julie A. Saugstad

1 July 2003 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
TLThomas Lila
Thomas Lila
TRThomas E. Renau
Thomas E. Renau
LWLori Wilson
Lori Wilson
JPJay Philips
Jay Philips
GNGeorges Natsoulis
Georges Natsoulis
JBJerry Buysse
Jerry Buysse
Compounds that selectively disrupt fungal mitosis have proven to be effective in controlling agricultural pests, but no specific mitotic inhibitor is available for the treatment of systemic mycoses in mammalian hosts. In an effort to identify novel mitotic inhibitors, we used a cell-based screening strategy that exploited the hypersensitivity of a yeast α-tubulin mutant strain to growth inhibition by antimitotic agents. The compounds identified inhibited yeast nuclear division and included one structural class of compounds shown to be fungus specific. MC-305,904 and structural analogs inhibited fungal cell mitosis and inhibited the in vitro polymerization of fungal tubulin but did not block mammalian cell microtubule function or mammalian tubulin polymerization. Extensive analysis of yeast mutations that specifically alter sensitivity to MC-305,904 structural analogs suggested that compounds in the series bind to a site on fungal β-tubulin near amino acid 198. Features of the proposed binding site explain the observed fungal tubulin specificity of the series and are consistent with structure-activity relationships among a library of related compounds.